Madrigal reclassifies two directors to balance board classes ahead of 2026 annual meeting

MADRIGAL PHARMACEUTICALS, INC.

Julian C. Baker reclassified from Class III to Class I, term expiring at 2026 Annual Meeting.
Daniel J. Brennan reclassified from Class II to Class I, effective April 22, 2026.
Reclassification aims to achieve more equal apportionment among three board classes.
Baker, Brennan, and James Daly nominated for re-election at June 17, 2026 meeting.
No changes to committee assignments as a result of the reclassification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.